BRAF

Oncogene
Serine/threonine-protein kinase B-raf UniProt accession P15056

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789).

May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

Source: UniProt

Monomer (PubMed:19710016). Homodimer (PubMed:19710016, PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers (PubMed:19710016).

Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer by phosphorylating BRAF at Thr-753. Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126).

Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1.

Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with RAF1, a ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714).

Interacts with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438).

Interacts with FNIP1 and FNIP2 (PubMed:27353360)

Source: UniProt
Nucleus, Cytoplasm, Cell membrane
Source: UniProt

Brain and testis

Source: UniProt
  • Unknown disease
  • Colorectal cancer (CRC)

    A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

  • Lung cancer (LNCR)

    A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

  • Familial non-Hodgkin lymphoma (NHL)

    Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

  • Cardiofaciocutaneous syndrome 1 (CFC1)

    A multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and intellectual disability. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition.

    Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices.

  • Noonan syndrome 7 (NS7)

    A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells.

  • LEOPARD syndrome 3 (LPRD3)

    A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.

  • Unknown disease
Source: UniProt
  • Spry regulation of FGF signaling
  • Frs2-mediated activation
  • ARMS-mediated activation
  • Signalling to p38 via RIT and RIN
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • SHOC2 M1731 mutant abolishes MRAS complex function
  • Gain-of-function MRAS complexes activate RAF signaling
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 2.94%
Lung Adenocarcinoma 5.93%
Lung Small Cell Carcinoma 0.89%
Lung Squamous Cell Carcinoma 2.72%
Oesophagus Adenocarcinoma 0.62%
Oesophagus Squamous Cell Carcinoma 1.06%
Pancreas Ductal Carcinoma 1.22%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to BRAF, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 4

NCT ID Condition Brief Title Phase Status
NCT02751177 Colorectal Cancer Metastatic Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer NA COMPLETED
NCT02537600 Malignant Melanoma Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis PHASE2 COMPLETED
NCT02313012 Neoplasm Metastasis Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors PHASE1 TERMINATED
NCT02109653 Non-Small Cell Lung Cancer Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC PHASE2 WITHDRAWN
NCT06337617 BRAF V600 Mutation Positive Melanoma A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma N/A COMPLETED
NCT07288203 Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma PHASE2 ACTIVE_NOT_RECRUITING
NCT01543113 Melanoma cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project NA COMPLETED
NCT05611229 Metastatic Melanoma Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden N/A COMPLETED
NCT01124669 Lung Cancer Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate N/A COMPLETED
NCT02441465 Malignant Melanoma, Cancer Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies PHASE1 COMPLETED